Clinical Trial Update: Clinical Trial of CD123-targeted CAR-NK Therapy for Relapse/refractory AML or BPDCN [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating a CD123-targeted CAR-NK cell therapy for relapsed/refractory acute myeloid leukemia or blastic plasmacytoid dendritic cell neo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Blastic Plasmacytoid Dendritic Cell Neoplasm

Drugs mentioned

• CD123-targeted CAR-NK therapy (CAR-NK cells targeting CD123)

Snippet

Sponsor: Chongqing Precision Biotech Co., Ltd | Conditions: AML (Acute Myeloid Leukemia), BPDCN (blastic Plasmacytoid Dendritic Cell Neoplasm) | Phase 1 | Status: RECRUITING